Vertex Pharmaceuticals Inc. (stock symbol: VRTX) is a publicly traded company listed on US. The company operates within the PHARMA sector and represents a significant player in its industry. As of the latest trading session, Vertex Pharmaceuticals Inc. is trading at $485.74 with a market capitalization of 125.00B.
Investors closely monitor Vertex Pharmaceuticals Inc. (VRTX) for its performance within the PHARMA sector. The stock currently shows a positive change of 0.09% in today's trading, reflecting bullish sentiment among market participants. The day's trading range has been between $483.02 (low) and $494.58 (high), with a trading volume of approximately 924.0K shares changing hands.
Vertex Pharmaceuticals Inc. has established itself as a notable name in the PHARMA industry, competing with other major players in the space. The company's stock performance is influenced by a variety of factors including quarterly earnings reports, economic indicators, industry trends, and broader market conditions. For Indian investors looking at VRTX, understanding the company's fundamentals, including its P/E ratio of 16.30 and dividend yield of 1.19%, is crucial for making informed investment decisions on both short-term trades and long-term holdings.
The PHARMA sector has been an important area of focus for market participants in recent trading sessions. Companies within this sector have demonstrated varying levels of performance based on macroeconomic factors, regulatory changes, and company-specific developments. Vertex Pharmaceuticals Inc. continues to adapt to changing market dynamics while maintaining its competitive positioning in the industry. Whether you are a day trader tracking short-term price movements or a long-term investor building a diversified portfolio, VRTX offers exposure to the PHARMA sector through a well-established publicly traded entity on US.
The current live price of Vertex Pharmaceuticals Inc. (VRTX) is $485.74 as of the most recent market data update on US. This price reflects the last traded value and changes in real-time during market hours. Today's trading session opened at $485.40, compared to the previous day's close of $485.30.
The intraday price action for VRTX shows a high of $494.58 and a low of $483.02, giving the stock a daily trading range of approximately $11.56. The stock has experienced a gain of 0.09% in today's session, representing a positive movement for shareholders. The total volume traded today stands at approximately 924.0K shares, indicating the level of market activity and liquidity for this stock.
Key Market Metrics for VRTX:
Market participants tracking VRTX should note that these prices are live and updated from seed_based. The market cap of 125.00B places Vertex Pharmaceuticals Inc. among significant companies listed on US. Trading volume of 924.0K shares suggests moderate trading activity in this stock.
Indian investors looking to purchase Vertex Pharmaceuticals Inc. (VRTX) shares have several reliable options through registered stockbrokers and trading platforms. The process of buying VRTX shares in India involves opening a demat and trading account with a SEBI-registered broker, completing the KYC (Know Your Customer) process, and funding the account to start trading. Below are the most popular platforms for investing in VRTX and other stocks on US.
Zerodha is India's largest retail stockbroker by active clients and offers a seamless platform for buying VRTX shares. With Zerodha's Kite platform, you can trade Vertex Pharmaceuticals Inc. stocks on NSE and BSE with zero brokerage on equity delivery trades. The account opening process is fully digital and can be completed in minutes. Open a Zerodha account here to start investing in VRTX with zero brokerage on delivery trades and flat ₹20 per trade on intraday and F&O.
Groww offers an intuitive mobile-first investment platform that is perfect for beginners looking to buy Vertex Pharmaceuticals Inc. shares. With a simple interface and educational resources, Groww makes it easy to invest in VRTX and thousands of other stocks and mutual funds. The platform offers zero account opening fees and zero brokerage on equity delivery. Sign up on Groww to begin your investment journey with Vertex Pharmaceuticals Inc. shares.
Angel One is another excellent choice for trading VRTX stocks, offering advanced charting tools, research reports, and expert recommendations. The platform provides free equity delivery trades and a powerful mobile trading app. Angel One's research team publishes regular analysis on Vertex Pharmaceuticals Inc. and other PHARMA sector stocks to help you make informed decisions. Open an Angel One account and get access to expert stock recommendations and advanced trading tools.
Steps to Buy VRTX Shares in India:
Disclaimer: Investments in the stock market are subject to market risks. Past performance does not guarantee future returns. Please consult a financial advisor before making investment decisions.
Understanding the price history of Vertex Pharmaceuticals Inc. (VRTX) is essential for both technical and fundamental analysis. The stock's current price of $485.74 can be better understood in the context of its recent trading patterns and long-term trends on US.
Today's price action shows VRTX opening at $485.40 compared to the previous close of $485.30. The intraday high of $494.58 and low of $483.02 represent the price boundaries for today's trading session. The positive movement of 0.09% provides insight into the day's market sentiment toward Vertex Pharmaceuticals Inc..
For technical analysis, traders monitor several key levels for VRTX:
The P/E ratio of 16.30 provides a valuation benchmark comparing 's stock price to its earnings per share. The dividend yield of 1.19% offers income investors an additional return component on top of potential price appreciation. These fundamental metrics, combined with technical price action, give investors a comprehensive view of VRTX\'s current market position and future prospects on US.
Investors are advised to use the interactive chart above to analyze VRTX\'s price trends across different timeframes — from intraday 1D charts for short-term traders to 1Y charts for long-term investors. The combination of fundamental analysis and technical chart patterns helps in making well-informed decisions about Vertex Pharmaceuticals Inc. stock in the PHARMA sector.
Here are other stocks in the PHARMA sector that investors tracking Vertex Pharmaceuticals Inc. (VRTX) may also be interested in. These companies operate in similar business areas and their performance can provide context for sector-wide trends on US.
The current live price of Vertex Pharmaceuticals Inc. (VRTX) is $485.74 as traded on US. This price is updated in real-time during market hours and reflects the latest transaction price. The stock opened today at $485.40 and has traded between $483.02 and $494.58 during the current session.
Indian investors can buy VRTX shares by opening a demat and trading account with any SEBI-registered stockbroker such as Zerodha, Groww, or Angel One. The account opening process requires Aadhaar and PAN card verification. Once your account is set up, you can fund it via UPI or net banking and start trading VRTX shares on US.
Vertex Pharmaceuticals Inc. operates in the PHARMA sector. The company is listed on US and its stock performance is influenced by sector-specific trends, economic conditions, regulatory changes, and company-specific developments within the PHARMA industry.
The current market capitalization of Vertex Pharmaceuticals Inc. is approximately 125.00B. Market cap is calculated by multiplying the current stock price by the total number of outstanding shares. This places Vertex Pharmaceuticals Inc. in the mid-cap category on US.
Whether VRTX is a good investment depends on your individual financial goals, risk tolerance, and investment horizon. The stock currently trades at $485.74 with a P/E ratio of 16.30 — comparatively reasonably valued. We recommend consulting a SEBI-registered financial advisor before making investment decisions. Use our interactive chart and market data above to conduct your own research on Vertex Pharmaceuticals Inc..